drugset / Trial / NCT01976195
High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
Phase 2
Withdrawn
Shandong University
Anhui Medical University · collabShenzhen Second People's Hospital · collabThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences · collabThe First Affiliated Hospital of Dalian Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone for the treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional high-dose dexamethasone mono-therapy.
Timeline
- Start
- 2013-10
- Primary completion
- 2014-12
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “No eligible patient was enrolled.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Subject | Thalidomide | Other / unclassified | 150 mg | — |